VXRT News and Press, Vaxart Inc. From 04/12/19

100% Survival Against Lethal H5N1 Avian Flu Challenge in Ferret Study Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scie...

Gainers: ATA (NASDAQ: ATAI ) +97% . Provention Bio (NASDAQ: PRVB ) +29% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +24% . Chimerix (NASDAQ: CMRX ) +22% . FARO Technologies (NASDAQ: FARO ) +17% . Soliton (NASDAQ: SOLY ) +15% . GEE Group (NYSEMKT: JOB ) +14% . Geron (NASDAQ: GERN ) ...

Vaxart (NASDAQ: VXRT )  -37%  on pricing stock offering. More news on: Vaxart, Inc., Zogenix, Inc., Zosano Pharma Corporation, Stocks on the move, Read more ...

Vaxart (NASDAQ: VXRT ) has priced its public offering of 9.1M common shares (including pre-funded warrants to purchase up to 8.2M common stock), and common warrants to purchase the same amount of shares at $1.10 per share and warrant, for gross proceeds of ~$10M. More news on: Vaxart, In...

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public offering of 9,090,010 shares of common stock (which includes p...

Gainers: Nordic American Offshore (NYSE: NAO ) +33%.  Melinta Therapeutics (NASDAQ: MLNT ) +23% . New Age Beverages (NASDAQ: NBEV ) +21% . Celldex Therapeutics (NASDAQ: CLDX ) +18% . Reliv International (NASDAQ: RELV ) +18% . Niu Technologies (NASDAQ: NIU ) +18% . Laredo Petrol...

Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in April. Vaxart will present the following: Post...

Vaxart (NASDAQ: VXRT ) completes dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine clinical trial with its oral norovirus GII.4 vaccine. More news on: Vaxart, Inc., Healthcare stocks news, Stocks on the move, Read more ...

First Oral Norovirus GII.4 Tablet Vaccine Used in Clinical Trial Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the completion of dosing of the lead-in cohort in the Ph...

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of its common stock at a price of $2.50 p...